COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)

Sage is exploring the use of brexanolone to potentially mitigate the morbidity and mortality associated with COVID-19 related ARDS.

As a company built on a scientific foundation of translational medicine, Sage is always looking at the ways our compounds may impact peripheral receptors systems. After several months of analysis of brexanolone clinical and pre-clinical data, we believe there is a sound rationale to test whether brexanolone may be able to mitigate the morbidity and mortality associated with COVID-19 related acute respiratory distress syndrome (ARDS).

Sage has received clearance from the U.S. FDA, under the Coronavirus Treatment Acceleration Program (CTAP), to initiate a Phase 3 study with brexanolone in patients with advanced COVID-19 related ARDS. The trial will involve several leading academic centers and build upon learnings from Sage’s extensive ICU and critical care data with brexanolone in super refractory status epilepticus (SRSE) trials to inform trial design.

As a company whose mission is making medicines that matter so people can get better, sooner, we believe that contributing to the collective efforts of the biopharma industry to fight the pandemic is the right thing to do.